Cardioverter –defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction

ConclusionIn a real-world setting, no benefit was evident for patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction by adding ICD therapy in a short-term follow-up of 12  months in contrast to patients with ischemic cardiomyopathy.Graphic abstract

Source: Clinical Research in Cardiology - June 23, 2019 Category: Cardiology Source Type: research